ProShare Advisors
PVLA

ProShare Advisors’s Palvella Therapeutics PVLA Stock Holding History

ProShare Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
+1,434
New +$174K ﹤0.01% 1588
2021
Q2 		– Sell
-177
Closed -$36K – 2413
2021
Q1 		$36K Buy
177
+30
+20% +$6.56K ﹤0.01% 2243
2020
Q4 		$29K Buy
+147
New +$30.6K ﹤0.01% 2077

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ProShare Advisors's PVLA Position: Q2 2026 in Review

ProShare Advisors opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 1,434 shares worth $219K. The stake represents ﹤0.01% of the portfolio and ranks #1588 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in PVLA as recently as Q1 2021.

ProShare Advisors first reported a position in PVLA in Q4 2020 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • ProShare Advisors held 1,434 shares of Palvella Therapeutics worth $219K as of Q2 2026.
  • Palvella Therapeutics was a new ProShare Advisors position in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1588 holding.
  • ProShare Advisors first reported a position in Palvella Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.